Delivery Order SPE2DB22D1106-SPE2DB25FFFG6
- Not listed
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a delivery order contract award from the Defense Logistics Agency (DLA) on July 22, 2025, for the supply of Belsomra 20 mg tablets in a quantity of 30 units. This is a firm fixed price delivery order with a ceiling value of $1,181.89 and an ultimate completion date of July 23, 2025. The award was made through open competition with no set-aside designation. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Belsomra 20 mg tablets (30-count packaging) valued at $1,305.88. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is set to be completed by September 4, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. Belsomra (suvorexant) is a prescription sleep...
- The Defense Logistics Agency awarded a delivery order valued at $1,119.24 to AmerisourceBergen Drug Corp for Belsomra 15 mg tablets (30-count supply) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award for pharmaceutical supply to support federal medical procurement needs. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Belsomra 20 mg tablets (30-count) at a ceiling value of $1,088.22. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is classified as a child contract, meaning it derives from a larger indefinite delivery vehicle. AmerisourceBergen's place of performance is located in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,101.78 to AmerisourceBergen Drug Corp for the supply of Belsomra 10 mg tablets (30-count units) on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation reflects a routine pharmaceutical supply transaction supporting federal medical procurement needs. The place of performance is listed as Conshohocken, Pennsylvania, which serves...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $2,674.38 to supply 30 tablets of Belsomra 10 mg, a prescription medication used to treat insomnia. This firm fixed price contract was competitively awarded without any set-aside designation and has an ultimate completion date of September 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency awarded a $381,960 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 30 boxes of the 10mg Belsomra sleep aid medication. To be performed in Conshohocken, Pennsylvania from September 22nd to 25th, 2023, this order was placed under an existing DLA pharmaceutical supply contract vehicle to support the military's medical readiness needs. No subcontractors or set aside designations were indicated. As a leader in distribution of pharmaceuticals...
- Defense Logistics Agency awarded a $483 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, on October 11, 2023 to supply Belsomra 15 mg tablets. Performance will occur in Conshohocken, Pennsylvania by October 12, 2023. No set-aside designation was used for this procurement of the prescription sleep medication. As a major distributor to government customers, Amerisourcebergen Drug Corp will fulfill this order from the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $1,024.62 to AmerisourceBergen Drug Corp for the supply of Belsomra (suvorexant) 20 mg tablets in a 30-count package. The contract, awarded on August 6, 2025, with an ultimate completion date of August 7, 2025, utilizes firm fixed price pricing with no set-aside designation. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.9 billion...
- Defense Logistics Agency awarded a $381 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the purchase of Belsomra 20 mg tablets. The contract has no set-aside designation and requires delivery to a location in Conshohocken, Pennsylvania by September 29, 2023. As a major provider of pharmaceuticals and medical supplies to the Department of Defense and other federal agencies, this order for a sleep medication supports the...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFFG6Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Belsomra 20 mg tablets (30-count units) under a firm fixed-price contract valued at $1,488.99. This non-set-aside award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion prime vendor agreement running through December 2026 that supports global pharmaceutical supply to military healthcare programs. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of August 27, 2025. This delivery order fulfills federal medical procurement requirements for Belsomra, a prescription sleep medication used to treat insomnia, reflecting AmerisourceBergen's established role as a critical pharmaceutical distributor for the Defense Health Agency and broader military healthcare systems. The transaction exemplifies the company's operational capability to execute competitively awarded contracts across a comprehensive therapeutic portfolio, ranging from specialty medications to generic drugs, while meeting the rapid fulfillment timelines required by defense medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 8/26/25 |